Andrea J. Mothe
399 Bathurst Street
Toronto, ON, Canada
Toronto, ON, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 35 publications
Elezanumab for the treatment of spinal cord injury: assessing the clinical development journey to date.
Journal: Expert opinion on investigational drugs
Published: July 07, 2026
Clinical stage anti-RGMa monoclonal antibody elezanumab promotes bladder recovery and neuroplasticity after traumatic spinal cord injury.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: March 15, 2026
Augmenting AMPA receptor signaling after spinal cord injury increases ependymal-derived neural stem/progenitor cell migration and promotes functional recovery.
Journal: Nature neuroscience
Published: June 14, 2024
Neutralizing RGMa with Elezanumab Promotes Cerebroprotection and Recovery in Rabbit Middle Cerebral Artery Occlusion.
Journal: Translational stroke research
Published: March 01, 2023
Excitotoxic glutamate levels drive spinal cord ependymal stem cell proliferation and fate specification through CP-AMPAR signaling.
Journal: Stem cell reports
Published: May 06, 2022
Delayed administration of elezanumab, a human anti-RGMa neutralizing monoclonal antibody, promotes recovery following cervical spinal cord injury.
Journal: Neurobiology of disease
Published: April 14, 2022
Elezanumab, a human anti-RGMa monoclonal antibody, promotes neuroprotection, neuroplasticity, and neurorecovery following a thoracic hemicompression spinal cord injury in non-human primates.
Journal: Neurobiology of disease
Published: January 25, 2021
Cholesterol synthesis inhibition promotes axonal regeneration in the injured central nervous system.
Cholesterol synthesis inhibition promotes axonal regeneration in the injured central nervous system.
Journal: Neurobiology of disease
Published: August 07, 2020
Delayed administration of the human anti-RGMa monoclonal antibody elezanumab promotes functional recovery including spontaneous voiding after spinal cord injury in rats.
Journal: Neurobiology of disease
Published: January 27, 2020
Unlocking the paradoxical endogenous stem cell response after spinal cord injury.
Journal: Stem cells (Dayton, Ohio)
Published: August 03, 2019
The leading edge: Emerging neuroprotective and neuroregenerative cell-based therapies for spinal cord injury.
Journal: Stem cells translational medicine
Published: April 29, 2019
Hyperphosphorylated Tau as a Novel Biomarker for Traumatic Axonal Injury in the Spinal Cord.
Journal: Journal of neurotrauma
Published: April 13, 2018
Last Updated: 09/26/2026